



Press Release

Saluggia, October 17th, 2011

START UP OF THE TREASURY SHARES BUY-BACK PLAN OF DIASORIN SPA

DiaSorin announces its willing to start up the treasury shares buy-back plan for the purpose, terms and provisions authorized by the Shareholders Meeting dated October 4th, 2011.

The purchase will be carried out for a first amount of DiaSorin common shares corresponding to maximum € 20,000,000.00 (twenty millions), within the final term of 18 months as of the aforementioned Shareholders' resolution.

The purchase will be executed at a unit price not lower by more than 20% or higher by more than 15% compared with the simple average of the closing prices of the DiaSorin Spa stock in the 10 stock market trading days preceding each individual buy transaction.

In the event of purchases, DiaSorin will communicate on a weekly basis to the Market and to the competent Authorities the transactions details along with any other information required by the applicable Laws.

For any further detail please refer to the Information Memorandum ("Relazione Informativa") of the Board of Directors published by DiaSorin under applicable Law, also on the Company's internet website www.diasorin.com.

The Chief Executive Officer

About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 23 companies based in Europe, North, Central and South America, Africa and Asia. It has about 1,500 employees, including more than 110 research and development specialists, and operates six manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA), Dublin (Ireland), Dartford (UK) and Johannesburg (SA). The last two were part of the Murex business operations, recently acquired from the Abbott Group. Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.DiaSorin.it

Contacts:

Investor Relations Officer

Laura Villa

DiaSorin S.p.A.

laura.villa@Diasorin.it

+39 0161487532

+39 348 15 11 542

Press Office

Carolina Mailander

c.mailander@mailander.it

+39 335 655 56 51

Bruno Caprioli

caprioli@mailander.it

+39 335 590 14 02